You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復旦張江(688505.SH):JAK1選擇性抑制劑治療潰瘍性結腸炎的II期臨牀試驗申請獲受理
格隆匯 11-19 17:15

格隆匯11月19日丨復旦張江(688505.SH)公佈,公司於近日收到國家藥品監督管理局核准簽發的《受理通知書》,FZJ-003膠囊即口服JAK1選擇性抑制劑(規格:25mg)用於治療潰瘍性結腸炎的II期臨牀試驗申請獲得受理。

潰瘍性結腸炎(Ulcerativecolitis,UC)是一種慢性、非特異性的腸道炎症性疾病,主要累及直腸和結腸,多呈反覆發作的慢性病程。該病受累區域通常出現黏膜炎症和黏膜潰瘍,其症狀表現為間歇性腹瀉、黏液膿血便、腹痛等。該病也可有全身表現,累及關節、皮膚或肝膽系統。潛在的併發症包括嚴重出血、中毒性結腸擴張和腸穿孔等。

公司此次向國家藥監局註冊申請事項為FZJ-003膠囊於治療類風濕關節炎I期臨牀試驗期間,擬開展新適應症的藥物II期臨牀試驗申請。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account